Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase NA 5Phase 1 3Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1

Interventions

pembrolizumab 109Cyclophosphamide 89fludarabine 70Carboplatin 57Injections 56Bevacizumab 49Specimen Handling 43Gemcitabine 41Magnetic Resonance Spectroscopy 40Paclitaxel 39Nivolumab 38venetoclax 36Dexamethasone 35Cisplatin 34Biopsy 34Temozolomide 31Docetaxel 29atezolizumab 27Capecitabine 27Oxaliplatin 26Fluorouracil 26Pemetrexed 24Irinotecan 24Azacitidine 24abemaciclib 23toripalimab 22Fulvestrant 22fludarabine phosphate 21Rituximab 21Leucovorin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × Fecal Microbiota Transplantation × Clear all
NCT05251389 2025-03-10

FMT to Convert Response to Immunotherapy

The Netherlands Cancer Institute

Phase 1/2 Recruiting
24 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡